The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) (BEZA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01165060

Recruitment Status : Completed

First Posted : July 19, 2010

Last Update Posted : August 10, 2011

Sponsor:

Collaborator:

The Stop ALD Foundation

Information provided by:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Description

Brief Summary:

X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder characterised by accumulation of very long chain fatty acids (VLCFA) in plasma and tissue. Presumably this accumulation is responsible for tissue damage. The disease can cause severe demyelinisation of the central nervous system usually causing death in childhood or progressive ambulatory problems in adults caused by a progressive myelopathy. For the latter category of patients no curative treatment is currently available. Recent investigations in human fibroblasts and mice identified bezafibrate as an agent that might reduce VLCFA in patients with X-ALD.

Objective of the study:

The trial is designed as an open-label pilot study. The main goal is to investigate if bezafibrate can reduce VLCFA in vivo in patient with X-ALD. If there is indeed a biochemical effect, a large follow-up study will be initiated with clinical outcome parameters.

Study design:

10 men with X-ALD will use bezafibrate during a period of 6 months (in combination with a low fat diet). On 6 different time points the participants will undergo a venipuncture for detecting possible side effects and to determine the biochemical outcome parameters.

Study population:

Adult men with X-linked adrenoleukodystrophy.

Intervention (if applicable):

Bezafibrate.

Primary study parameters/outcome of the study:

The primary outcome parameters are cholesterol levels (total-, LDL, and HDL) and levels of triglycerides in plasma, VLCFA levels in plasma, leukocytes and erythrocytes and also C26:0-lyso-PC in bloodspots.

Secondary study parameters/outcome of the study (if applicable):

Secondary outcome parameters are side-effects (subjective and abnormalities in the safety lab).

Condition or disease	Intervention/treatment	Phase
X-linked Adrenoleukodystrophy Adrenomyeloneuropathy	Drug: Bezafibrate	Not Applicable

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	10 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD)
Study Start Date :	July 2010
Actual Primary Completion Date :	August 2011
Actual Study Completion Date :	August 2011

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: RNAse T2-deficient leukoencephalopathy X-linked adrenoleukodystrophy Leukoencephalopathy with vanishing white matter Megalencephalic leukoencephalopathy with subcortical cysts

Genetic and Rare Diseases Information Center resources: X-linked Adrenoleukodystrophy Adrenomyeloneuropathy Peroxisomal Biogenesis Disorders Hypoadrenalism

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bezafibrate All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.	Drug: Bezafibrate Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets. Other Name: Bezalip retard.

Outcome Measures

Primary Outcome Measures :

Very long chain fatty acids (VLCFA; C22:0, C24:0 and C26:0) in plasma, lymphocytes and erythrocytes. [ Time Frame: 24 weeks ]

Secondary Outcome Measures :

Side effects [ Time Frame: At 4, 8, 12, 16, 20 and 24 weeks. ]
Cholesterol (total-, HDL, and LDL-cholesterol) in plasma. [ Time Frame: 24 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

an age of 18 years or older
capable of giving informed consent and capable of visiting the hospital for follow-up visits
no contra-indications for the use of bezafibrate, e.g. kidney- and/or liver disease.
confirmed X-ALD, AMN phenotype (confirmed by VLCFA analysis or analysis of the ABCD1 gene)

Exclusion Criteria:

use of medication that lowers cholesterol and/or triglycerides (e.g. statins)
liver disease or and increase in serum CK of more than 3 times the baseline level
treatment with Lorenzo's oil in the 8 weeks preceding the trial

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01165060

Locations


Netherlands
Academisch Medisch Centrum
Amsterdam, NH, Netherlands, 1100 DD

Sponsors and Collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

The Stop ALD Foundation

Investigators


Principal Investigator:	Bwee Tien Poll - The, MD, PhD	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Engelen M, Tran L, Ofman R, Brennecke J, Moser AB, Dijkstra IM, Wanders RJ, Poll-The BT, Kemp S. Bezafibrate for X-linked adrenoleukodystrophy. PLoS One. 2012;7(7):e41013. doi: 10.1371/journal.pone.0041013. Epub 2012 Jul 20.


Responsible Party:	Department of (pediatric) neurology, Academisch Medisch Centrum, Amsterdam, The Netherlands
ClinicalTrials.gov Identifier:	NCT01165060 History of Changes
Other Study ID Numbers:	MEC 09/278
First Posted:	July 19, 2010 Key Record Dates
Last Update Posted:	August 10, 2011
Last Verified:	July 2010

Keywords provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):


X-ALD AMN adrenomyeloneuropathy phenotype

Additional relevant MeSH terms:


Adrenoleukodystrophy Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Hereditary Central Nervous System Demyelinating Diseases Leukoencephalopathies Demyelinating Diseases Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Genetic Diseases, X-Linked	Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolism, Inborn Errors Peroxisomal Disorders Metabolic Diseases Adrenal Insufficiency Adrenal Gland Diseases Endocrine System Diseases Bezafibrate Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents

To Top